<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301963</url>
  </required_header>
  <id_info>
    <org_study_id>CASE3A10</org_study_id>
    <secondary_id>NCI-2011-00186</secondary_id>
    <nct_id>NCT01301963</nct_id>
  </id_info>
  <brief_title>Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide</brief_title>
  <official_title>Comparison of Plerixafor and G-CSF Versus G-CSF Alone for Stem Cell Mobilization in Patients With Multiple Myeloma Previously Treated With Lenalidomide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies filgrastim (G-CSF) with or without plerixafor in treating
      patients with multiple myeloma (MM) previously treated with lenalidomide. Giving
      colony-stimulating factors, such as G-CSF, and plerixafor helps stem cells move from the
      patient's bone marrow to the blood so they can be collected and stored
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Ability to reach target collection of 5 x 10^6 CD34+ cells/Kg with =&lt; 2 days of
      leukaphereses using one of two mobilization regimens.

      SECONDARY OBJECTIVES:

      I. Percentage of patients achieving target goal CD34+ cell dose (as above) in =&lt; 5 days of
      leukaphereses.

      II. Compare collections between different mobilization regimens in those patients who are
      crossed over from one mobilization regimen to the other.

      III. Compare days of apheresis, need for hospitalization during mobilization, and need for
      remobilization between mobilizing groups.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive G-CSF subcutaneously (SC) once daily (QD) on days 1-8.

      ARM II: Patients receive G-CSF SC QD on days 1-7 and plerixafor SC QD on days 4-7.

      After completion of study treatment, patients are followed up at 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Accrual
  </why_stopped>
  <start_date>July 2011</start_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to Reach Target Collection of 5 x 10^6 CD34+ Cells/kg</measure>
    <time_frame>In =&lt; 2 days of leukaphereses</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Target Goal CD34+ Cells Dose</measure>
    <time_frame>In =&lt; 5 days of leukaphereses</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Hematopoietic Stem Cells/kg Collections Between Different Mobilization Regimens in Those Patients Who Are Crossed Over From One Mobilization Regimen to the Other</measure>
    <time_frame>By day 1</time_frame>
    <description>Patients will be randomized to receive either G-CSF or Plerixafor with G-CSF. All patients will undergo at least 2 days of leukopheresis. Cells/kg between these 2 arms will be compared. For those patients that do not reach the target goal will undergo a wash-out period and cross over to the other study arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Days of Apheresis Between Mobilization Groups</measure>
    <time_frame>Day 1</time_frame>
    <description>Using the Wilcoxon Rand Sum Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Need for Hospitalization During Mobilization Between Mobilization Groups</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Need for Remobilization Between Mobilization Groups</measure>
    <time_frame>Day 1</time_frame>
    <description>Using the Chi-square test or Fisher's exact test, as appropriate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive G-CSF SC QD on days 1-4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>plerixafor</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>AMD 3100</other_name>
    <other_name>Mozobil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of MM by International Myeloma Working Group Criteria

          -  In first or second complete or partial remission or stable refractory but not actively
             progressing myeloma according to the classifications provided by The Center for
             International Blood &amp; Marrow Transplant Research

          -  Received at least 2 cycles of lenalidomide therapy

          -  Patients with MM scheduled to undergo stem cell harvest for possible allogeneic stem
             cell transplant (ASCT)

          -  At least 2 weeks since last exposure to lenalidomide

          -  Eastern Cooperative Oncology Group performance status of 0 or 1

          -  Prior to the start of mobilization:

               -  white blood cell count &gt;/= 2.5 x 10^9/L

               -  absolute neutrophil count &gt;/= 1.2 x 10^9/L

               -  platelet count &gt;/=100 x 10^9/L

               -  creatinine clearance &gt;/= 30mL/minute

          -  If childbearing potential, must either agree to complete abstinence from heterosexual
             intercourse or effective means of contraception during stem cell mobilization; female
             patients will undergo pregnancy test prior to stem cell mobilization therapy

        Exclusion Criteria:

          -  Had prior autologous or allogeneic transplantation

          -  Received pegfilgrastim within 3 weeks or G-CSF within 14 days of first dose of G-CSF
             for mobilization

          -  Failed previous hematopoietic stem cell collections or collection attempts

          -  Received radiation therapy to the pelvic area

          -  Received lenalidomide within 2 weeks of first dose of G-CSF for mobilization

          -  Had received experimental therapy within 4 weeks of enrolling in study

          -  Current or prior history of other malignancies, excluding basal cell carcinoma of the
             skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hien Duong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hillard Lazarus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <results_first_submitted>July 7, 2014</results_first_submitted>
  <results_first_submitted_qc>July 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 6, 2014</results_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I: Control</title>
          <description>Patients receive G-CSF SC QD on days 1-4.
filgrastim: Given SC</description>
        </group>
        <group group_id="P2">
          <title>Arm II: Experimental</title>
          <description>Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.
plerixafor: Given SC
filgrastim: Given SC</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients receive G-CSF SC QD on days 1-4.
filgrastim: Given SC</description>
        </group>
        <group group_id="B2">
          <title>Arm II</title>
          <description>Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.
plerixafor: Given SC
filgrastim: Given SC</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.40" spread="4.16"/>
                    <measurement group_id="B2" value="56.25" spread="8.18"/>
                    <measurement group_id="B3" value="53.00" spread="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ability to Reach Target Collection of 5 x 10^6 CD34+ Cells/kg</title>
        <time_frame>In =&lt; 2 days of leukaphereses</time_frame>
        <population>due to low enrollment (10% of anticipated participants), no analysis is being done on data collected in this study</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: Control</title>
            <description>Patients receive G-CSF SC QD on days 1-4.
filgrastim: Given SC</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Experimental</title>
            <description>Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.
plerixafor: Given SC
filgrastim: Given SC</description>
          </group>
        </group_list>
        <measure>
          <title>Ability to Reach Target Collection of 5 x 10^6 CD34+ Cells/kg</title>
          <population>due to low enrollment (10% of anticipated participants), no analysis is being done on data collected in this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Target Goal CD34+ Cells Dose</title>
        <time_frame>In =&lt; 5 days of leukaphereses</time_frame>
        <population>Due to low enrollment (10% of anticipated participants), no analysis is being done on data collected in this study</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: Control</title>
            <description>Patients receive G-CSF SC QD on days 1-4.
filgrastim: Given SC</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Experimental</title>
            <description>Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.
plerixafor: Given SC
filgrastim: Given SC</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Target Goal CD34+ Cells Dose</title>
          <population>Due to low enrollment (10% of anticipated participants), no analysis is being done on data collected in this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Hematopoietic Stem Cells/kg Collections Between Different Mobilization Regimens in Those Patients Who Are Crossed Over From One Mobilization Regimen to the Other</title>
        <description>Patients will be randomized to receive either G-CSF or Plerixafor with G-CSF. All patients will undergo at least 2 days of leukopheresis. Cells/kg between these 2 arms will be compared. For those patients that do not reach the target goal will undergo a wash-out period and cross over to the other study arm.</description>
        <time_frame>By day 1</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Days of Apheresis Between Mobilization Groups</title>
        <description>Using the Wilcoxon Rand Sum Test</description>
        <time_frame>Day 1</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Need for Hospitalization During Mobilization Between Mobilization Groups</title>
        <time_frame>Day 1</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Need for Remobilization Between Mobilization Groups</title>
        <description>Using the Chi-square test or Fisher's exact test, as appropriate.</description>
        <time_frame>Day 1</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I: Control</title>
          <description>Patients receive G-CSF SC QD on days 1-4.
filgrastim: Given SC</description>
        </group>
        <group group_id="E2">
          <title>Arm II: Experimental</title>
          <description>Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.
plerixafor: Given SC
filgrastim: Given SC</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hien Duong, MD</name_or_title>
      <organization>CCCC</organization>
      <phone>216-445-5531</phone>
      <email>duongh@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

